SCHEMBL4716748

SCHEMBL4716748

Cc1cc(NC(=O)Nc2cccc(C#Cc3cnc(N)nc3)c2)on1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LCK P06239 5/20 0.48
TEK Q02763 4/20 0.48
HTR2C P28335 2/20 0.47
KDR P35968 10/20 0.43
PDGFRB P09619 4/20 0.43
BTK Q06187 1/20 0.43
SMN1; SMN2 Q16637 2/20 0.42
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
ALDH1A1 P00352 3/20 0.41
PKM P14618 1/20 0.41
GRM5 P41594 1/20 0.40
ROCK2 O75116 1/20 0.39
MAP4K4 O95819 1/20 0.39
CHEK2 O96017 1/20 0.39
CSF1R P07333 1/20 0.39
LYN P07948 1/20 0.39
RET P07949 1/20 0.39
FGFR1 P11362 1/20 0.39
FLT1 P17948 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4720324 0.88 TEK (0.51) LCKTEKHTR2CKDRPDGFRB
SCHEMBL4718568 0.84 ALDH1A1 (0.60) LCKTEKKDRPDGFRBSMN1; SMN2
SCHEMBL4720860 0.81 KDR (0.57) LCKTEKKDRPDGFRBSMN1; SMN2
SCHEMBL4715335 0.81 LCK (0.46) LCKTEKKDRPDGFRBSMN1; SMN2
SCHEMBL4719789 0.81 LCK (0.54) LCKTEKKDRPDGFRBSMN1; SMN2
SCHEMBL4715827 0.79 MEN1 (0.60) LCKTEKHTR2CKDRSMN1; SMN2
SCHEMBL4716331 0.79 MEN1 (0.60) KDRPDGFRBNPC1RAB9ACSF1R
SCHEMBL3580009 0.79 LCK (0.59) LCKTEKKDRPDGFRBGRM5
SCHEMBL4718570 0.79 MEN1 (0.50) LCKTEKKDRPDGFRBSMN1; SMN2
SCHEMBL4717465 0.78 LCK (0.56) LCKTEKKDRPDGFRBSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1737463-B1 PYRIMIDINES WITH TIE2 (TEK) ACTIVITY ASTRAZENECA AB (SE) 2008-12-03 EP claimed
EP-1737463-B1 PYRIMIDINES WITH TIE2 (TEK) ACTIVITY ASTRAZENECA AB (SE) 2008-12-03 EP disclosed
US-20080108608-A1 Pyrimidines With Tie2 (Tek) Activity ASTRAZENECA AB (SE) 2008-05-08 US disclosed
EP-1737463-A1 PYRIMIDINES WITH TIE2 (TEK) ACTIVITY AstraZeneca AB (SE) 2007-01-03 EP disclosed
WO-2005060970-A1 PYRIMIDINES WITH TIE2 (TEK) ACTIVITY ASTRAZENECA AB (SE) 2005-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080108608-A1 Pyrimidines With Tie2 (Tek) Activity TIE1, TEK, TEKT1 LCK 391/4885TEK 2/4885HTR2C 2883/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.